Skip to content

Phase II clinical study of EGCG in preventing radiation oral mucositis

Phase II clinical study of EGCG in preventing radiation oral mucositis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052871
Enrollment
Unknown
Registered
2021-11-06
Start date
2021-11-01
Completion date
Unknown
Last updated
2022-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head-neck tumor

Interventions

Group 1:EGCG
Group 2:Physiological saline

Sponsors

Shandong Cancer Hospital and Institute
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with locally advanced nasopharyngeal carcinoma were diagnosed by pathology and received simultaneous radiotherapy and chemotherapy for the first time; 2. ECOG 0 or 1; 3. The estimated survival time is more than 6 months; 4. 18-70 years old; 5. Normal bone marrow reserve function; 6. Normal renal function; 7. Normal liver function; 8. The electrocardiogram is normal; 9. The subjects agreed and signed the informed consent form; 10. There is no obvious inflammation of mouth and throat before radiotherapy, dental caries should be repaired first, residual roots should be removed as appropriate, and radiotherapy will be carried out after recovery.

Exclusion criteria

Exclusion criteria: 1. Those who receive targeted therapy and other treatments at the same time; 2. Allergic to EGCG or tea; 3. Pregnant or lactating patients.

Design outcomes

Primary

MeasureTime frame
The efficiency of EGCG;

Secondary

MeasureTime frame
Change in blood biochemical indicators;Safty;

Countries

China

Contacts

Public ContactZhu Wanqi

Shandong Cancer Hospital and Institute

zlyykyk@sina.com+86 531 67626624

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026